Using PRP treatment after ACL reconstruction to improve recovery
The Efficiency and Safety of Platelet-rich Plasma Intra-articular Injections After Anterior Cruciate Ligament Reconstruction: MRI and Clinical Outcome Analysis.
This study is testing if using platelet-rich plasma (PRP) after ACL surgery can help people heal better and lower their chances of developing arthritis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Sponsor | Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz Academic / other |
| Locations | 1 site (Torun) |
| Trial ID | NCT06442319 on ClinicalTrials.gov |
What this trial studies
This study investigates the efficiency and safety of platelet-rich plasma (PRP) treatment following anterior cruciate ligament (ACL) reconstruction. ACL injuries are common and often lead to long-term complications such as osteoarthritis. The trial aims to assess whether PRP can enhance healing and reduce the risk of arthritis after surgery. Participants will be monitored for their recovery and any adverse effects associated with the treatment.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 18-45 who have undergone ACL reconstruction and meet specific health criteria.
Not a fit: Patients with metabolic diseases, previous knee surgeries, or those who have received intra-articular injections may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve recovery outcomes and reduce the incidence of arthritis in patients after ACL reconstruction.
How similar studies have performed: Other studies have shown promising results with PRP treatment in similar contexts, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * subject is 18-45 years old * subject has BMI \< 40 kg/m2 * subject had ACL reconstrution * small asymptomatic meniscal lesions that won't require repair * subject must be willing to abstain from other intra-articular treatments of the knee for the duration of the study. * subject is willing to discontinue all analgesics including nonsteroidal anti-inflammatory drugs (NSAIDs), except tramadol and paracetamol, at least one month before the synovial fluid aspiration and through the completion of the study * subject is able to understand and comply with the requirements of the study and voluntarily provides consent Exclusion Criteria: * subject has a history of metabolic diseases, endocrine disorders, rheumatic and connective tissue diseases, cancer, hormonal contraception, steroid therapy, antibiotic therapy * subject had an intraarticular injection into the affected joint * subject had previous operations (beside ACL reconstruction) or fractures of the affected limb * subject has a history of nicotine, alcohol, or drug addiction * subject has a meniscal tear that requires suturing or total meniscectomy seen on MRI * subject has multi-ligament knee injuries or multi-organ injury * subject has significant varus or valgus deformity greater than 10 degrees in either knee, determined by an X-ray
Where this trial is running
Torun
- Dawid Szwedowski — Torun, Poland (Recruiting)
Study contacts
- Study coordinator: Dawid Szwedowski, MD, PhD
- Email: dszwedow@yahoo.com
- Phone: 608075237
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.